Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...
It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...
Health and Me on MSN3h
FDA Approves Tremfya For Active Crohn's DiseaseCrohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...
The agency OK’d an artificial vessel to restore blood flow in patients, even though its own scientists flagged questionable ...
The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...
13h
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
McGill researchers found lecanemab may be less effective in women, prompting calls for more personalized treatment and ...
Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene ...
A new international study has offered hope that Alzheimer’s disease may one day be preventable—at least in people genetically ...
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback